122 related articles for article (PubMed ID: 3035588)
21. Ribonucleotide reductase of herpes simplex virus type 2 resembles that of herpes simplex virus type 1.
Averett DR; Furman PA; Spector T
J Virol; 1984 Dec; 52(3):981-3. PubMed ID: 6092726
[TBL] [Abstract][Full Text] [Related]
22. Virus-drug resistance: thymidine kinase-deficient (TK-) mutants of herpes simplex virus. Therapeutic approaches.
de Clercq E
Ann Ist Super Sanita; 1987; 23(4):841-7. PubMed ID: 2837935
[No Abstract] [Full Text] [Related]
23. Studies on the differential mechanisms of inhibition of ribonucleotide reductase by specific inhibitors of the non-heme iron subunit.
Sato A; Bacon PE; Cory JG
Adv Enzyme Regul; 1984; 22():231-41. PubMed ID: 6089512
[TBL] [Abstract][Full Text] [Related]
24. Drug-resistant herpes simplex virus in vitro and after acyclovir treatment in an immunocompromised patient.
Schnipper LE; Crumpacker CS; Marlowe SI; Kowalsky P; Hershey BJ; Levin MJ
Am J Med; 1982 Jul; 73(1A):387-92. PubMed ID: 6285729
[TBL] [Abstract][Full Text] [Related]
25. Effects of ribonucleotide reductase inhibition on pyrimidine deoxynucleotide metabolism in acyclovir-treated cells infected with herpes simplex virus type 1.
Karlsson A; Harmenberg J
Antimicrob Agents Chemother; 1988 Jul; 32(7):1100-2. PubMed ID: 2847642
[TBL] [Abstract][Full Text] [Related]
26. [Clinical utility of susceptibility testing of herpes simplex virus to acyclovir].
Otegui M; Rabella N; Labeaga R; Herrero M; Margall N; Muñoz JM; Prats G
Rev Esp Quimioter; 2001 Dec; 14(4):351-7. PubMed ID: 11856981
[TBL] [Abstract][Full Text] [Related]
27. Resistance of herpes simplex virus to antiviral agents. Is it clinically important?
Crumpacker C
Drugs; 1983 Nov; 26(5):373-7. PubMed ID: 6315331
[No Abstract] [Full Text] [Related]
28. Potentiation of antiherpetic activity of acyclovir by ribonucleotide reductase inhibition.
Spector T; Averett DR; Nelson DJ; Lambe CU; Morrison RW; St Clair MH; Furman PA
Proc Natl Acad Sci U S A; 1985 Jun; 82(12):4254-7. PubMed ID: 2987969
[TBL] [Abstract][Full Text] [Related]
29. [Chemotherapy to thymidine kinase producing virus (HSV-1, HSV-2, VZV) infection].
Goto H; Shimada K
Nihon Rinsho; 1989 Feb; 47(2):378-83. PubMed ID: 2542661
[No Abstract] [Full Text] [Related]
30. Oligopeptides inhibit the ribonucleotide reductase of herpes simplex virus by causing subunit separation.
McClements W; Yamanaka G; Garsky V; Perry H; Bacchetti S; Colonno R; Stein RB
Virology; 1988 Jan; 162(1):270-3. PubMed ID: 2827385
[TBL] [Abstract][Full Text] [Related]
31. Ribonucleotide reductase from wild type and hydroxyurea-resistant chinese hamster ovary cells.
Lewis WH; Wright JA
J Cell Physiol; 1978 Oct; 97(1):87-97. PubMed ID: 568630
[TBL] [Abstract][Full Text] [Related]
32. Isolation and initial characterization of a series of Chlamydia trachomatis isolates selected for hydroxyurea resistance by a stepwise procedure.
Tipples G; McClarty G
J Bacteriol; 1991 Aug; 173(16):4932-40. PubMed ID: 1860812
[TBL] [Abstract][Full Text] [Related]
33. Development of acyclovir-resistant herpes simplex virus early during the treatment of herpes neonatorum.
Levin MJ; Weinberg A; Leary JJ; Sarisky RT
Pediatr Infect Dis J; 2001 Nov; 20(11):1094-7. PubMed ID: 11734722
[TBL] [Abstract][Full Text] [Related]
34. Peptidomimetic inhibitors of herpes simplex virus ribonucleotide reductase with improved in vivo antiviral activity.
Moss N; Beaulieu P; Duceppe JS; Ferland JM; Garneau M; Gauthier J; Ghiro E; Goulet S; Guse I; Jaramillo J; Llinas-Brunet M; Malenfant E; Plante R; Poirier M; Soucy F; Wernic D; Yoakim C; Déziel R
J Med Chem; 1996 Oct; 39(21):4173-80. PubMed ID: 8863795
[TBL] [Abstract][Full Text] [Related]
35. Prophylaxis: a strategy to minimise antiviral resistance.
Ambinder RF; Burns WH; Lietman PS; Saral R
Lancet; 1984 May; 1(8387):1154-5. PubMed ID: 6144879
[No Abstract] [Full Text] [Related]
36. Neutralization of herpes simplex virus ribonucleotide reductase activity by an oligopeptide-induced antiserum directed against subunit H2.
Cohen EA; Gaudreau P; Brazeau P; Langelier Y
J Virol; 1986 Dec; 60(3):1130-3. PubMed ID: 2431161
[TBL] [Abstract][Full Text] [Related]
37. Activation by thymidine kinase and potent antiherpetic activity of 2'-nor-2'-deoxyguanosine (2'NDG).
Ashton WT; Karkas JD; Field AK; Tolman RL
Biochem Biophys Res Commun; 1982 Oct; 108(4):1716-21. PubMed ID: 6295389
[No Abstract] [Full Text] [Related]
38. Potential for combined therapy with 348U87, a ribonucleotide reductase inhibitor, and acyclovir as treatment for acyclovir-resistant herpes simplex virus infection.
Safrin S; Schacker T; Delehanty J; Hill E; Corey L
J Med Virol; 1993; Suppl 1():146-9. PubMed ID: 8245882
[TBL] [Abstract][Full Text] [Related]
39. Role of viral ribonucleotide reductase in the increase of dTTP pool size in herpes simplex virus-infected Vero cells.
Daikoku T; Yamamoto N; Maeno K; Nishiyama Y
J Gen Virol; 1991 Jun; 72 ( Pt 6)():1441-4. PubMed ID: 1646284
[TBL] [Abstract][Full Text] [Related]
40. Herpes simplex virus type 1 ribonucleotide reductase null mutants induce lesions in guinea pigs.
Turk SR; Kik NA; Birch GM; Chiego DJ; Shipman C
Virology; 1989 Dec; 173(2):733-5. PubMed ID: 2556851
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
